{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:17:19Z","timestamp":1790101039511,"version":"4.0.1"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chitotriosidase is an enzyme produced and secreted in large amounts by activated macrophages, especially macrophages loaded with phagocytozed glycosphingolipid in Gaucher disease. Macrophages phagocytose decayed blood cells that contain a lot of sphingolipid-rich cell membranes. In Gaucher disease, due to a deficit in beta-glucocerebrosidase activity, the phagocytozed substrate glucocerebroside cannot undergo further catabolism. In such a situation, macrophages secrete chitotriosidase in proportion to the degree of overload. Gaucher disease (GD) is a recessively inherited disorder resulting in storage of glucosylceramide (GlcCer) in lysosomes of tissue macrophages. It is directly caused by the deficiency of beta-glucocerebrosidase (GBA) activity. Chitotriosidase has been measured systematically each year in the same group of 49 patients with type 1 and 3 GD for over 20 years. Our analysis showed that chitotriosidase is very sensitive biomarker to enzyme replacement therapy (ERT). The response to treatment introduction is of an almost immediate nature, lowering pathologically high chitotriosidase levels by a factor of 2 in a time scale of 8 months, on average. Long term enzyme replacement therapy (ERT) brings chitotriosidase activity close to reference values. Finally, reducing the dose of ERT quickly boosts chitotriosidase activity, but restoring the initial dose of treatment brings chitotriosidase level of activity back onto the decreasing time trajectory.<\/jats:p>","DOI":"10.3390\/biom13030436","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T03:23:36Z","timestamp":1677468216000},"page":"436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients\u2014A Qualitative and Quantitative Approach"],"prefix":"10.3390","volume":"13","author":[{"given":"Paulina","family":"Szyma\u0144ska-Ro\u017cek","sequence":"first","affiliation":[{"name":"Faculty of Mathematics, Informatics, and Mechanics, University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Czartoryska","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazina","family":"Kleinotiene","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-8375","authenticated-orcid":false,"given":"Patryk","family":"Lipi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nutrition and Metabolic Diseases, The Children\u2019s Memorial Health Institute, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nutrition and Metabolic Diseases, The Children\u2019s Memorial Health Institute, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-6407","authenticated-orcid":false,"given":"Agnieszka","family":"\u0141ugowska","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"ref_1","unstructured":"Valle, D.L., Antonarakis, S., Ballabio, A., Beaudet, A.L., and Mitchell, G.A. (2019). The Online Metabolic and Molecular Bases of Inherited Disease, McGraw Hill. Available online: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225546056."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity: A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF02436762","article-title":"Elevated plasma chitotriosidase activity in various lysosomal storage disorders","volume":"18","author":"Guo","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/08035320510028094","article-title":"Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases","volume":"94","author":"Aerts","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","article-title":"Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies","volume":"34","author":"Aerts","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0079-6603(00)66030-0","article-title":"Molecular and cell biology of acid beta-glucosidase and prosaposin","volume":"66","author":"Qi","year":"2001","journal-title":"Prog. Nucleic Acid. Res. Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0009-9120(98)00030-7","article-title":"Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT)","volume":"31","author":"Czartoryska","year":"1998","journal-title":"Clin. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0009-9120(99)00098-3","article-title":"Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease","volume":"33","author":"Czartoryska","year":"2000","journal-title":"Clin. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2007.02.042","article-title":"Monitoring of Gaucher patients with a novel chitotriosidase assay","volume":"381","author":"Schoonhoven","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"Hendriks","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1750-1172-9-95","article-title":"Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model","volume":"9","author":"Vigan","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2019.236083","article-title":"Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data","volume":"106","author":"Raskovalova","year":"2021","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene: Nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","article-title":"Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease","volume":"35","author":"Deegan","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00365513.2017.1303191","article-title":"Modelling long-term evolution of chitotriosidase in non-neuronopathic Gaucher disease","volume":"77","author":"Drugan","year":"2017","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/8904_2012_158","article-title":"Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 Italian Gaucher type I patients","volume":"7","author":"Deroma","year":"2013","journal-title":"JIMD Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2010.09.005","article-title":"Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage","volume":"46","author":"Giraldo","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_20","first-page":"81","article-title":"Imiglucerase in the treatment of Gaucher disease: A history and perspective","volume":"6","author":"Deegan","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00005-014-0308-8","article-title":"Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3","volume":"63","author":"Machaczka","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Blau, N., Duran, M., and Gibson, K.M. (2008). Laboratory Guide to the Methods in Biochemical Genetics, Springer.","DOI":"10.1007\/978-3-540-76698-8"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ymgme.2018.02.004","article-title":"Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes\u2014A statistical insight","volume":"123","year":"2018","journal-title":"Mol. Genet. Metab."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/3\/436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:42:08Z","timestamp":1760121728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/3\/436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["biom13030436"],"URL":"https:\/\/doi.org\/10.3390\/biom13030436","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}